Invent Individualized Medicine with International Impact

InxMed is a clinical-stage biotech company focus on “Best-in-Disease Combination Strategy”. With disease biology as the source of innovation, InxMed is committed to building a platform with fast clinical transformation and proof-of-concept capability, and becoming a global leading company from China in the 2.0 era of new drug R&D.



Our TeamMembers of the InxMed core team have held senior R&D and management positions in top-ranking MNC companies such as Roche, Novartis, MSD, Schering-Plough, GlaxoSmithKline and Johnson & Johnson, who led teams to complete clinical development and registration of a dozen drugs, including Keytruda, Gardasil in China, having rich experience in all aspects of innovative drug research, development, clinical transformation, proof-of-concept, and marketing.


PipelineWe are building up a differentiated pipeline with potential of intrinsic synergy to combat cancer. We are exploring varies of combinational use to maximize the value of each asset and generate impactful treatment regimens for cancer patients.

PartneringPartnering with the best early stage science and clinical-stage programs is our top priority. We are dedicated to building strong partnership with top-tier research institutes, biotech and pharmaceutical companies. Our initial focus is to partner with assets with potential synergy with our current portfolio to enable us to select the winning combination and deliver meaningful benefit in the fight against cancer.


Copyright © 2019  InxMed  ICP备10238728号  Powered by